利用酒石酸-resistant酸性磷酸酶5b建立模型模拟日本骨质疏松患者接受唑来膦酸治疗后的骨密度变化
本研究基于306例原发性骨质疏松患者的3410次血清TRACP-5b浓度和1146次腰椎L2-L4骨密度值,构建数学模型描述TRACP-5b和骨密度的时间变化,并从基线骨密度及基线、12周TRACP-5b值预测两次年度唑来膦酸治疗后2年内的骨密度百分比变化,模拟的90%预测区间几乎覆盖各时间点观察到的骨密度百分比分布,预测值与观察值相当。
要点
- 基于基线骨密度及基线、12周TRACP-5b值可预测两次年度唑来膦酸治疗后2年内的骨密度百分比变化
- 模拟的90%预测区间几乎覆盖各时间点观察到的骨密度百分比分布
- 该模型可在唑来膦酸治疗初期向患者告知其预测的治疗反应
核心结论
- 这是首个利用患者背景特征和TRACP-5b早期反应预测两次年度唑来膦酸治疗后2年内骨密度的模型。
- 该模型可在唑来膦酸治疗初期向患者告知其预测的治疗反应。
研究设计与样本
- 研究纳入306例原发性骨质疏松患者,使用3410次血清TRACP-5b浓度和1146次腰椎L2-L4骨密度值构建数学模型。
- 模型用于描述TRACP-5b和骨密度的时间依赖性变化。
主要发现
- 从患者基线骨密度及基线、12周TRACP-5b值,通过所获模型预测了2年内骨密度相对基线的百分比变化(%BMD)。
- 模拟的90%预测区间几乎覆盖各时间点观察到的%BMD分布,预测值与观察值相当。
临床怎么用
- 该模型可在唑来膦酸治疗初期向患者告知其预测的治疗反应。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Annual intravenous administration of zoledronic acid is used in the treatment of osteoporosis. A mathematical model was developed to predict bone mineral density up to 2 years after two annual doses of zoledronic acid from the early values of a bone resorption marker in osteoporosis patients. INTRODUCTION: The measurement of bone mineral density (BMD) has been used as a surrogate marker instead of the observation of incident fractures to detect the efficacy of treatment. However, this method requires a long time to obtain significant changes. On the other hand, bone resorption markers respond to bone resorption inhibitors within a few weeks. Therefore, the aim of this study was to develop a mathematical model predicting long-term BMD after two annual doses of zoledronic acid (ZOL) using the early response of a bone resorption marker in osteoporosis patients. METHODS: The model was constructed using 3410 tartrate-resistant acid phosphatase 5b (TRACP-5b) serum concentrations and 1146 lumbar spine (L2-L4) BMD values from 306 patients with primary osteoporosis. A mathematical model was developed to describe the time-dependent profiles of TRACP-5b and BMD. RESULTS: The percentage changes from baseline of the BMD (%BMD) at up to 2 years were predicted from patients' baseline BMD and baseline and 12-week TRACP-5b values by the model obtained. The simulated 90% prediction interval almost covered the observed %BMD distribution at each time point, and the predictions were comparable to the observed %BMD. CONCLUSIONS: This is the first model to predict BMD for up to 2 years following two annual doses of ZOL using patients' background characteristics and the early response of TRACP-5b. This model allows us to inform patients at the initial stage of ZOL treatment of their predicted response to treatment.
引用
- Mori Y, Kasai H, Ose A, et al. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker. Osteoporos Int. 2018. PMID: 29423715. doi:10.1007/s00198-018-4376-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。